{"id":"https://openalex.org/W3013236696","doi":"https://doi.org/10.1158/1535-7163.mct-19-0774","title":"Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab","display_name":"Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab","publication_year":2020,"publication_date":"2020-03-30","ids":{"openalex":"https://openalex.org/W3013236696","doi":"https://doi.org/10.1158/1535-7163.mct-19-0774","mag":"3013236696","pmid":"https://pubmed.ncbi.nlm.nih.gov/32229606"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-19-0774","doi":"https://doi.org/10.1158/1535-7163.mct-19-0774","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-19-0774","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025446353","display_name":"Beth Hutchins","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Beth Hutchins","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022587464","display_name":"Gary C. Starling","orcid":"https://orcid.org/0000-0001-9879-4336","observed_orcids":["https://orcid.org/0000-0001-9879-4336"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gary C. Starling","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":"https://orcid.org/0000-0001-9879-4336","affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052325628","display_name":"Mark A. McCoy","orcid":"https://orcid.org/0000-0003-3994-6605","observed_orcids":["https://orcid.org/0000-0003-3994-6605"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark A. McCoy","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":"https://orcid.org/0000-0003-3994-6605","affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027778157","display_name":"Danuta J. Herzyk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Danuta Herzyk","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112515757","display_name":"Frederique M. Poulet","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Frederique M. Poulet","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015564877","display_name":"John Dulos","orcid":"https://orcid.org/0009-0003-0928-9971","observed_orcids":["https://orcid.org/0009-0003-0928-9971"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Dulos","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey","2Galapagos, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"2Galapagos, Leiden, The Netherlands","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100418744","display_name":"Liu Liming","orcid":"https://orcid.org/0000-0001-8337-6932","observed_orcids":["https://orcid.org/0000-0001-8337-6932"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Liming Liu","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":"https://orcid.org/0000-0001-8337-6932","affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109399966","display_name":"Soonmo Peter Kang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Soonmo Peter Kang","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023191992","display_name":"Laurence Fayadat\u2010Dilman","orcid":"https://orcid.org/0000-0001-6285-8924","observed_orcids":["https://orcid.org/0000-0001-6285-8924"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laurence Fayadat-Dilman","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":"https://orcid.org/0000-0001-6285-8924","affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041693462","display_name":"Mark Hsieh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Hsieh","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035749706","display_name":"Christine L. Andrews","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christine L. Andrews","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025576427","display_name":"Gulesi Ayanoglu","orcid":"https://orcid.org/0000-0002-0272-6169","observed_orcids":["https://orcid.org/0000-0002-0272-6169"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gulesi Ayanoglu","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":"https://orcid.org/0000-0002-0272-6169","affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110259604","display_name":"Constance Cullen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Constance Cullen","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey","3Apollo Biologics Consulting, Los Angeles, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"3Apollo Biologics Consulting, Los Angeles, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041768709","display_name":"Ren\u00e9 de Waal Malefyt","orcid":"https://orcid.org/0000-0002-2663-383X","observed_orcids":["https://orcid.org/0000-0002-2663-383X"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I4387152537","display_name":"Synthekine","ror":"https://ror.org/01j84fh13","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152537"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rene de Waal Malefyt","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey","4Synthekine, Inc., Menlo Park, California"],"raw_orcid":"https://orcid.org/0000-0002-2663-383X","affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"4Synthekine, Inc., Menlo Park, California","institution_ids":["https://openalex.org/I4387152537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103497871","display_name":"Robert A. Kastelein","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I4387152537","display_name":"Synthekine","ror":"https://ror.org/01j84fh13","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152537"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert A. Kastelein","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey","4Synthekine, Inc., Menlo Park, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"4Synthekine, Inc., Menlo Park, California","institution_ids":["https://openalex.org/I4387152537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055567366","display_name":"Sabine Le Saux","orcid":"https://orcid.org/0000-0002-3125-7242","observed_orcids":["https://orcid.org/0000-0002-3125-7242"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sabine Le Saux","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":"https://orcid.org/0000-0002-3125-7242","affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Julie Lee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julie Lee","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079161652","display_name":"Sophie Li","orcid":"https://orcid.org/0000-0002-4762-6911","observed_orcids":["https://orcid.org/0000-0002-4762-6911"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sophie Li","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084759453","display_name":"Dan Malashock","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dan Malashock","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051844715","display_name":"Svetlana Sadekova","orcid":"https://orcid.org/0000-0002-0113-8306","observed_orcids":["https://orcid.org/0000-0002-0113-8306"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Svetlana Sadekova","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062623763","display_name":"George Soder","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"George Soder","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":"https://orcid.org/0000-0002-8468-6323","affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013558609","display_name":"Hans van Eenennaam","orcid":"https://orcid.org/0000-0003-0099-3738","observed_orcids":["https://orcid.org/0000-0003-0099-3738"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I4210092553","display_name":"AIMM Therapeutics (Netherlands)","ror":"https://ror.org/0027p4q12","country_code":"NL","type":"company","lineage":["https://openalex.org/I4210092553"]}],"countries":["NL","US"],"is_corresponding":false,"raw_author_name":"Hans van Eenennaam","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey","5AIMM Therapeutics B.V., Amsterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"5AIMM Therapeutics B.V., Amsterdam, The Netherlands","institution_ids":["https://openalex.org/I4210092553"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109346365","display_name":"Aarron T. Willingham","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aarron Willingham","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102013792","display_name":"Ying Yu","orcid":"https://orcid.org/0000-0003-1472-7035","observed_orcids":["https://orcid.org/0000-0003-1472-7035"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ying Yu","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044564994","display_name":"Michel Streuli","orcid":"https://orcid.org/0000-0001-8566-4065","observed_orcids":["https://orcid.org/0000-0001-8566-4065"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michel Streuli","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey","6Pionyr Immunotherapeutics, South San Francisco, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"6Pionyr Immunotherapeutics, South San Francisco, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036346275","display_name":"Gregory J. Carven","orcid":"https://orcid.org/0000-0002-8468-6323","observed_orcids":["https://orcid.org/0000-0002-8468-6323"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I4210101493","display_name":"Scholar Rock (United States)","ror":"https://ror.org/01036m381","country_code":"US","type":"education","lineage":["https://openalex.org/I4210101493"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gregory J. Carven","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey","7Scholar Rock, Inc., Cambridge, Massachusetts"],"raw_orcid":"https://orcid.org/0000-0002-8468-6323","affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"7Scholar Rock, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210101493"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043865752","display_name":"Andrea van Elsas","orcid":"https://orcid.org/0000-0002-2966-114X","observed_orcids":["https://orcid.org/0000-0002-2966-114X","https://orcid.org/0009-0001-3426-2653"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I4210127859","display_name":"Aduro BioTech (United States)","ror":"https://ror.org/03h7fe682","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127859"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrea van Elsas","raw_affiliation_strings":["1Merck & Co., Inc., Kenilworth, New Jersey","8Aduro Biotech, Inc., Berkeley, California"],"raw_orcid":"https://orcid.org/0000-0002-2966-114X","affiliations":[{"raw_affiliation_string":"1Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"8Aduro Biotech, Inc., Berkeley, California","institution_ids":["https://openalex.org/I4210127859"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5025446353"],"corresponding_institution_ids":["https://openalex.org/I1285764155"],"apc_list":null,"apc_paid":null,"fwci":0.8033,"has_fulltext":false,"cited_by_count":23,"citation_normalized_percentile":{"value":0.71536896,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"19","issue":"6","first_page":"1298","last_page":"1307"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T14072","display_name":"Immunotoxicology and immune responses","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":1.0},{"id":"https://openalex.org/keywords/anti-pd-1-antibody","display_name":"anti-PD-1","score":0.9150000214576721},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.7160000205039978},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.9739999771118164},{"id":"https://openalex.org/keywords/pd-l2","display_name":"PD-L2","score":0.9959999918937683},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.9509999752044678},{"id":"https://openalex.org/keywords/humanized-antibody","display_name":"humanized monoclonal antibody","score":0.7540000081062317},{"id":"https://openalex.org/keywords/cynomolgus-monkeys","display_name":"Macaca fascicularis","score":0.8870000243186951},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.890999972820282},{"id":"https://openalex.org/keywords/toxicokinetics","display_name":"toxicokinetics","score":0.9860000014305115},{"id":"https://openalex.org/keywords/t-cell-activation","display_name":"T cell activation","score":0.6850000023841858},{"id":"https://openalex.org/keywords/interleukin-2","display_name":"interleukin-2","score":0.6710000038146973},{"id":"https://openalex.org/keywords/interferon-gamma","display_name":"interferon-gamma","score":0.8970000147819519},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.5839999914169312},{"id":"https://openalex.org/keywords/antibody-affinity","display_name":"antibody affinity","score":0.4309999942779541}],"concepts":[{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.8822821974754333},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.6226943731307983},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.559916615486145},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4818228781223297},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4628670811653137},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.4514518976211548},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.4364824593067169},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.43323785066604614},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3836868703365326},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3408714234828949},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3245096206665039},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007963","descriptor_name":"Leukocytes, Mononuclear","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D007963","descriptor_name":"Leukocytes, Mononuclear","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D007963","descriptor_name":"Leukocytes, Mononuclear","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008252","descriptor_name":"Macaca fascicularis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008807","descriptor_name":"Mice, Inbred BALB C","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D014018","descriptor_name":"Tissue Distribution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018675","descriptor_name":"Toxicity Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060890","descriptor_name":"B7-H1 Antigen","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D060890","descriptor_name":"B7-H1 Antigen","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D060890","descriptor_name":"B7-H1 Antigen","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D061027","descriptor_name":"Programmed Cell Death 1 Ligand 2 Protein","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D061027","descriptor_name":"Programmed Cell Death 1 Ligand 2 Protein","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D061027","descriptor_name":"Programmed Cell Death 1 Ligand 2 Protein","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.mct-19-0774","doi":"https://doi.org/10.1158/1535-7163.mct-19-0774","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-19-0774","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:32229606","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32229606","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307776","display_name":"Merck","ror":"https://ror.org/02891sr49"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":46,"referenced_works":["https://openalex.org/W1490650258","https://openalex.org/W1538902372","https://openalex.org/W1749548564","https://openalex.org/W1967078099","https://openalex.org/W1976770085","https://openalex.org/W1977381583","https://openalex.org/W1995808589","https://openalex.org/W1996374378","https://openalex.org/W2016732129","https://openalex.org/W2029086221","https://openalex.org/W2031373281","https://openalex.org/W2033672531","https://openalex.org/W2037840717","https://openalex.org/W2047502920","https://openalex.org/W2060070314","https://openalex.org/W2063264144","https://openalex.org/W2069971243","https://openalex.org/W2083025888","https://openalex.org/W2095692889","https://openalex.org/W2098205979","https://openalex.org/W2099092516","https://openalex.org/W2099609050","https://openalex.org/W2107556275","https://openalex.org/W2109485845","https://openalex.org/W2111161262","https://openalex.org/W2116193045","https://openalex.org/W2136332525","https://openalex.org/W2155464214","https://openalex.org/W2163184426","https://openalex.org/W2257999935","https://openalex.org/W2473759462","https://openalex.org/W2542082502","https://openalex.org/W2550990550","https://openalex.org/W2586232813","https://openalex.org/W2587048937","https://openalex.org/W2592133876","https://openalex.org/W2592666036","https://openalex.org/W2606939149","https://openalex.org/W2613452439","https://openalex.org/W2626773261","https://openalex.org/W2740931940","https://openalex.org/W2749319028","https://openalex.org/W2898336695","https://openalex.org/W2913202470","https://openalex.org/W2925322150","https://openalex.org/W4230195560"],"related_works":["https://openalex.org/W2099609050","https://openalex.org/W1988314473","https://openalex.org/W2473759462","https://openalex.org/W3029868931","https://openalex.org/W4238534569","https://openalex.org/W4232349440","https://openalex.org/W4402131488","https://openalex.org/W4231895300","https://openalex.org/W2890811159","https://openalex.org/W3093022498"],"abstract_inverted_index":{"Abstract":[0],"The":[1,213],"programmed":[2],"cell":[3],"death":[4],"1":[5],"(PD-1)":[6],"pathway":[7],"represents":[8],"a":[9,33],"major":[10],"immune":[11,27,73,120],"checkpoint,":[12],"which":[13],"may":[14],"be":[15],"engaged":[16],"by":[17,125],"cells":[18,66,160],"in":[19,122,144,152,189,231],"the":[20,41,48,61,88,106,221],"tumor":[21,69,147],"microenvironment":[22],"to":[23,45,67,77,96],"overcome":[24],"active":[25],"T-cell":[26,123,166],"surveillance.":[28],"Pembrolizumab":[29,75,103,113,171,183],"(Keytruda\u00ae,":[30],"MK-3475)":[31],"is":[32],"potent":[34],"and":[35,52,56,71,79,86,92,98,108,116,137,141,151,157,168,187,193,225],"highly":[36],"selective":[37],"humanized":[38],"mAb":[39],"of":[40,64,90,111,134,208],"IgG4/kappa":[42],"isotype":[43],"designed":[44],"directly":[46],"block":[47],"interaction":[49],"between":[50],"PD-1":[51,82,95],"its":[53],"ligands,":[54],"PD-L1":[55,97],"PD-L2.":[57],"This":[58],"blockade":[59],"enhances":[60,164],"functional":[62],"activity":[63,224],"T":[65,159],"facilitate":[68],"regression":[70],"ultimately":[72],"rejection.":[74],"binds":[76,104],"human":[78,91,115,145,156,198,232],"cynomolgus":[80,93,117,190],"monkey":[81,94,118,191],"with":[83,100,155,220],"picomolar":[84],"affinity":[85],"blocks":[87],"binding":[89],"PD-L2":[99],"comparable":[101],"potency.":[102],"both":[105],"C\u2032D":[107],"FG":[109],"loops":[110],"PD-1.":[112],"overcomes":[114],"PD-L1\u2013mediated":[119],"suppression":[121],"cultures":[124],"enhancing":[126],"IL2":[127,169],"production":[128,143],"following":[129],"staphylococcal":[130],"enterotoxin":[131],"B":[132],"stimulation":[133],"healthy":[135],"donor":[136],"cancer":[138],"patient":[139],"cells,":[140],"IFN\u03b3":[142,167],"primary":[146],"histoculture.":[148],"Ex":[149],"vivo":[150],"vitro":[153],"studies":[154,195],"primate":[158,203],"show":[161],"that":[162,227],"pembrolizumab":[163,217],"antigen-specific":[165],"production.":[170],"does":[172],"not":[173],"mediate":[174],"FcR":[175],"or":[176],"complement-driven":[177],"effector":[178],"function":[179],"against":[180],"PD-1\u2013expressing":[181],"cells.":[182],"displays":[184],"dose-dependent":[185],"clearance":[186],"half-life":[188],"pharmacokinetic":[192],"toxicokinetic":[194],"typical":[196],"for":[197,216],"IgG4":[199],"antibodies.":[200],"In":[201],"nonhuman":[202],"toxicology":[204],"studies,":[205],"no":[206],"findings":[207],"toxicologic":[209],"significance":[210],"were":[211],"observed.":[212],"preclinical":[214],"data":[215],"are":[218],"consistent":[219],"clinical":[222,233],"anticancer":[223],"safety":[226],"has":[228],"been":[229],"demonstrated":[230],"trials.":[234]},"counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2020-04-03T00:00:00"}